Expression and Single Nucleotide Polymorphism of Poly (ADPRibose) Polymerase-1 in Gastrointestinal Tumours: Clinical Involvement.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Current Medicinal Chemistry

• Publication date

  2017-05-31

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2174/0929867324666170316115039PMID 28302009
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Involvement of bleomycin hydrolase and poly(ADP-ribose) polymerase-1 in Ubc9-mediated resistance to chemotherapy agents.

  2017cited by this paper
• PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes

  2017cited by this paper
• Inhibiting poly ADP-ribosylation increases fatty acid oxidation and protects against fatty liver disease.

  2017cited by this paper
• PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis.

  2017cited by this paper
• PET of Poly (ADP-Ribose) Polymerase Activity in Cancer: Preclinical Assessment and First In-Human Studies.

  2017cited by this paper
• Novel poly (ADP-ribose) polymerase inhibitor, AZD2281, enhances radiosensitivity of both normoxic and hypoxic esophageal squamous cancer cells.

  2016cited by this paper
• Poly(ADP-Ribose) Polymerases: New Players in the Pathogenesis of Exocrine Pancreatic Diseases.

  2016cited by this paper
• Lentivirus-mediated inhibition of USP39 suppresses the growth of gastric cancer cells via PARP activation.

  2016cited by this paper
• Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer?

  2016cited by this paper
• Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer.

  2016cited by this paper
• Expression of an Oncogenic BARD1 Splice Variant Impairs Homologous Recombination and Predicts Response to PARP-1 Inhibitor Therapy in Colon Cancer

  2016cited by this paper
• A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers.

  2016cited by this paper
• Iodinated benzimidazole PARP radiotracer for evaluating PARP1/2 expression in vitro and in vivo.

  2016cited by this paper
• Correlation of Helicobacter pylori and interleukin-8 mRNA expression in high risk gastric cancer population prediction.

  2016cited by this paper
• ATM Expression Predicts Veliparib and Irinotecan Sensitivity in Gastric Cancer by Mediating P53-Independent Regulation of Cell Cycle and Apoptosis

  2016cited by this paper
• Arsenite-loaded nanoparticles inhibit PARP-1 to overcome multidrug resistance in hepatocellular carcinoma cells

  2016cited by this paper
• Helicobacter pylori-induced chronic inflammation causes telomere shortening of gastric mucosa by promoting PARP-1-mediated non-homologous end joining of DNA.

  2016cited by this paper
• Hypermethylated DNA as a biomarker for colorectal cancer: a systematic review

  2016cited by this paper
• Targeting deficient DNA damage repair in gastric cancer

  2016cited by this paper
• Glutathione S-transferase M1 polymorphism and esophageal cancer risk: An updated meta-analysis based on 37 studies.

  2016cited by this paper
• PARP inhibitor combination therapy.

  2016cited by this paper
• A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187

  2016cited by this paper
• Pancreatic ductal adenocarcinoma in BRCA2 mutation carriers.

  2016cited by this paper
• High PARP-1 expression is associated with tumor invasion and poor prognosis in gastric cancer

  2016cited by this paper
• Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors

  2016cited by this paper
• Pancreatic adenocarcinoma.

  2016cited by this paper
• Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.

  2015cited by this paper
• The role of NF-κB in PARP-inhibitor-mediated sensitization and detoxification of arsenic trioxide in hepatocellular carcinoma cells.

  2015cited by this paper
• The Role of Poly(ADP-ribose) Polymerase-1 in Rheumatoid Arthritis

  2015cited by this paper
• Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

  2015cited by this paper
• Effectiveness and safety of poly (ADP-ribose) polymerase inhibitors in cancer therapy: A systematic review and meta-analysis

  2015cited by this paper
• Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer.

  2015cited by this paper
• Trapping Poly(ADP-Ribose) Polymerase

  2015cited by this paper
• E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling

  2015cited by this paper
• Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma

  2015cited by this paper
• Deciphering the Insights of Poly(ADP‐Ribosylation) in Tumor Progression

  2015cited by this paper
• Treatment with the PARP inhibitor, niraparib, sensitizes colorectal cancer cell lines to irinotecan regardless of MSI/MSS status

  2015cited by this paper
• Tumor suppressive effect of PARP1 and FOXO3A in gastric cancers and its clinical implications

  2015cited by this paper
• Synergistic suppressive effect of PARP-1 inhibitor PJ34 and HDAC inhibitor SAHA on proliferation of liver cancer cells

  2015cited by this paper
• Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma.

  2015cited by this paper
• Anticancer bioactive peptides suppress human colorectal tumor cell growth and induce apoptosis via modulating the PARP-p53-Mcl-1 signaling pathway

  2015cited by this paper
• Synergistic cytotoxicity of the poly (ADP‐ribose) polymerase inhibitor ABT‐888 and temozolomide in dual‐drug targeted magnetic nanoparticles

  2015cited by this paper
• The Use of Olaparib (AZD2281) Potentiates SN-38 Cytotoxicity in Colon Cancer Cells by Indirect Inhibition of Rad51-Mediated Repair of DNA Double-Strand Breaks

  2014cited by this paper
• PARP inhibition and the radiosensitizing effects of the PARP inhibitor ABT-888 in in vitro hepatocellular carcinoma models

  2014cited by this paper
• Oridonin induces apoptosis and cell cycle arrest of gallbladder cancer cells via the mitochondrial pathway

  2014cited by this paper
• Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase

  2014cited by this paper
• Poly (ADP-ribose) polymerase inhibition synergizes with the NF-κB inhibitor DHMEQ to kill hepatocellular carcinoma cells.

  2014cited by this paper
• Two DNA repair gene polymorphisms on the risk of gastrointestinal cancers: a meta-analysis

  2014cited by this paper
• Association between the PARP1 Val762Ala Polymorphism and Cancer Risk: Evidence from 43 Studies

  2014cited by this paper
• PARP-1 Expression is Increased in Colon Adenoma and Carcinoma and Correlates with OGG1

  2014cited by this paper
• BRCA1, BRCA2, PALB2, and CDKN2A Mutations in Familial Pancreatic Cancer (FPC): A PACGENE Study

  2014cited by this paper
• Poly (ADP‐ribose) polymerase‐1 is a key mediator of liver inflammation and fibrosis

  2014cited by this paper
• Parp‐1 genetic ablation in Ela–myc mice unveils novel roles for Parp‐1 in pancreatic cancer

  2014cited by this paper
• PARP inhibitors for anticancer therapy.

  2014cited by this paper
• Novel mutations of the PARP-1 gene associated with colorectal cancer in the Saudi population.

  2014cited by this paper
• Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines

  2014cited by this paper
• PARP-1 Val762Ala Polymorphism and Risk of Cancer: A Meta-Analysis Based on 39 Case-Control Studies

  2014cited by this paper
• Combination of AZD2281 (Olaparib) and GX15-070 (Obatoclax) results in synergistic antitumor activities in preclinical models of pancreatic cancer.

  2014cited by this paper
• Combined Inhibition of Wee1 and PARP1/2 for Radiosensitization in Pancreatic Cancer

  2014cited by this paper
• In vitro and in vivo enhancement of chemoradiation using the oral PARP inhibitor ABT-888 in colorectal cancer cells.

  2013cited by this paper
• Reduced ADP‐ribosylation by PARP1 natural polymorphism V762A and by PARP1 inhibitors enhance Hepatitis B virus replication

  2013cited by this paper
• Inhibition of arginine ADP-ribosyltransferase 1 reduces the expression of poly(ADP-ribose) polymerase-1 in colon carcinoma.

  2013cited by this paper
• The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines

  2013cited by this paper
• Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

  2013cited by this paper
• BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency

  2013cited by this paper
• PARP-1 Regulates Resistance of Pancreatic Cancer to TRAIL Therapy

  2013cited by this paper
• Selected Polymorphisms of Base Excision Repair Genes and Pancreatic Cancer Risk in Japanese

  2012cited by this paper
• Role of poly(ADP‐ribose) polymerases in the regulation of inflammatory processes

  2012cited by this paper
• High nuclear poly‐(ADP‐ribose)‐polymerase expression is prognostic of improved survival in pancreatic cancer

  2012cited by this paper
• Association between PARP‐1 V762A polymorphism and cancer susceptibility: a meta‐analysis

  2012cited by this paper
• Colorectal carcinoma: Pathologic aspects.

  2012cited by this paper
• Targeting the DNA damage response in oncology: past, present and future perspectives

  2012cited by this paper
• PARP1 polymorphisms increase the risk of gastric cancer in a Chinese population.

  2012cited by this paper
• Colorectal cancers differ in respect of PARP-1 protein expression.

  2012cited by this paper
• The combination of olaparib and camptothecin for effective radiosensitization

  2012cited by this paper
• MSH3 Mediates Sensitization of Colorectal Cancer Cells to Cisplatin, Oxaliplatin, and a Poly(ADP-ribose) Polymerase Inhibitor*

  2011cited by this paper
• Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer.

  2011cited by this paper
• Signaling mechanism of poly(ADP-ribose) polymerase-1 (PARP-1) in inflammatory diseases.

  2011cited by this paper
• Inhibition of poly (ADP-ribose) polymerase-1 enhances doxorubicin activity against liver cancer cells.

  2011cited by this paper
• Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers.

  2011cited by this paper
• Iniparib in metastatic triple-negative breast cancer.

  2011cited by this paper
• MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers.

  2011cited by this paper
• Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1

  2011cited by this paper
• Targeting poly(ADP-ribose) polymerase activity for cancer therapy

  2010cited by this paper
• Polymorphisms in Base Excision Repair Genes as Colorectal Cancer Risk Factors and Modifiers of the Effect of Diets High in Red Meat

  2010cited by this paper
• The properties of tumor-initiating cells from a hepatocellular carcinoma patient's primary and recurrent tumor.

  2010cited by this paper
• Poly(ADP-ribose) polymerase inhibition modulates experimental acute necrotizing pancreatitis-induced oxidative stress, bacterial translocation and neopterin concentrations in rats

  2010cited by this paper
• PARP inhibition: PARP1 and beyond

  2010cited by this paper
• Inhibition of poly adenosine diphosphate‐ribose polymerase decreases hepatocellular carcinoma growth by modulation of tumor‐related gene expression

  2010cited by this paper
• Pancreatic cancer.

  2010cited by this paper
• In vitro and In vivo Radiosensitization of Glioblastoma Cells by the Poly (ADP-Ribose) Polymerase Inhibitor E7016

  2009cited by this paper
• ABT-888 Confers Broad In vivo Activity in Combination with Temozolomide in Diverse Tumors

  2009cited by this paper
• Wnt signaling inside the nucleus

  2008cited by this paper
• Systematic review: primary and secondary prevention of gastrointestinal cancers with antioxidant supplements

  2008cited by this paper
• Poly(ADP-ribose) polymerase-1 inhibition increases expression of heat shock proteins and attenuates heat stroke-induced liver injury

  2008cited by this paper
• PJ34, an inhibitor of PARP-1, suppresses cell growth and enhances the suppressive effects of cisplatin in liver cancer cells.

  2008cited by this paper
• Therapeutic treatment with poly(ADP‐ribose) polymerase inhibitors attenuates the severity of acute pancreatitis and associated liver and lung injury

  2007cited by this paper
• DNA Repair Single-Nucleotide Polymorphisms in Colorectal Cancer and their Role as Modifiers of the Effect of Cigarette Smoking and Alcohol in the Singapore Chinese Health Study

  2007cited by this paper
• Modulation of transcription by PARP-1: consequences in carcinogenesis and inflammation.

  2007cited by this paper
• PARP1 Val762Ala polymorphism reduces enzymatic activity.

  2007cited by this paper

• Molecular Study of the Poly (ADP-ribose) Polymerase-1 Gene as a Promotor of Inflammation-Driven Colorectal Carcinoma.

  2025cites this paper
• PARP1-targeted fluorescence molecular endoscopy as novel tool for early detection of esophageal dysplasia and adenocarcinoma

  2024cites this paper
• Identification of PARP-1 in cancer stem cells of gastrointestinal cancers: A preliminary study

  2021cites this paper
• Identification of PARP-1 in cancer stem cells of gastrointestinal cancers: A preliminary study

  2021influential citation
• Single-nucleotide polymorphism screening and RNA sequencing of key messenger RNAs associated with neonatal hypoxic-ischemia brain damage

  2019cites this paper
• The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview

  2019cites this paper
• PARP-1 protects against colorectal tumor induction, but promotes inflammation-driven colorectal tumor progression

  2018cites this paper